Key takeaway
In this pilot trial of prostate cancer patients on androgen deprivation therapy (ADT), 12 weeks of supervised resistance training improved lean mass (d = 0.9), body fat % (d = 1.1) and strength compared with stretching (p < 0.05), while metabolic syndrome measures and physical function did not change. Only 32 of 37 randomized people took part, so the results are preliminary.
Study design
Randomised trial
Reading basis
Published abstract
Reading focus
Comparator & uncertainty
The research question
ADT for prostate cancer causes muscle loss, fat gain and changes that raise the risk of metabolic syndrome, and no exercise program had yet improved both body composition and metabolic syndrome. This pilot trial tested resistance training for 12 weeks, and explored whether adding whey protein would give extra benefit.
Who and how
Pilot randomized controlled trial (NCT01909440) in prostate cancer patients on ADT, randomized to resistance training plus protein (TRAINPRO), resistance training (TRAIN), protein only (PRO) or stretching control (STRETCH). Exercise groups trained under supervision 3 days per week for 12 weeks; non-exercise groups did a home stretching program, and TRAINPRO and PRO received 50 g per day of whey protein. The primary outcome was change in lean mass by dual energy x-ray absorptiometry. Secondary outcomes included sarcopenia, body fat %, strength, physical function, quality of life and metabolic syndrome components.
What it found
The authors’ reported results. Read each estimate with its population and uncertainty.
- 137 participants were randomized and 32 took part in the intervention (13 in exercise groups, 19 in non-exercise groups). At baseline 43.8% were sarcopenic and 40.6% met criteria for metabolic syndrome.
- 2Compared with the non-exercise groups, exercise improved lean mass (d = 0.9), sarcopenia prevalence (d = 0.8), body fat % (d = 1.1), strength (d = 0.8-3.0) and prostate cancer-specific quality of life (d = 0.9), all p < 0.05.
- 3No significant group differences were seen for physical function or metabolic syndrome variables, except waist circumference (d = 0.8).
- 4Protein supplementation alone gave no additional benefit for body composition.
Limits & uncertainty
- 1This is a pilot with 32 participants analyzed in four arms, then compared as exercise (13) versus non-exercise (19), so groups were small and uneven and estimates are imprecise.
- 2Several outcomes were tested, and the protein question was exploratory, so some p < 0.05 findings may be chance.
- 3The abstract gives effect sizes (d) without confidence intervals or absolute changes, making the practical size hard to judge.
- 4Training was supervised in a trial setting, and this reading is based on the abstract only.
What to take from it
For men on ADT, supervised resistance training looks like a promising way to hold on to muscle and strength and cut body fat, but this small pilot did not show gains in metabolic syndrome or physical function. Anyone with prostate cancer should plan exercise with their oncology team.
Reading your own data
Training logs of weights lifted and repetitions, plus body weight and waist measurement, can show your progress. Body fat percentages from smart scales are not the same as DXA scans, so use the same scale under the same conditions and watch trends over weeks.
How to read this evidence
Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.
Authors’ structured abstract English
The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.
Background
Prostate cancer patients on androgen deprivation therapy (ADT) experience adverse effects such as lean mass loss, known as sarcopenia, fat gain, and changes in cardiometabolic factors that increase risk of metabolic syndrome (MetS). Resistance training can increase lean mass, reduce body fat, and improve physical function and quality of life, but no exercise interventions in prostate cancer patients on ADT have concomitantly improved body composition and MetS. This pilot trial investigated 12 weeks of resistance training on body composition and MetS changes in prostate cancer patients on ADT. An exploratory aim examined if a combined approach of training and protein supplementation would elicit greater changes in body composition.
Methods
Prostate cancer patients on ADT were randomized to resistance training and protein supplementation (TRAINPRO), resistance training (TRAIN), protein supplementation (PRO), or control stretching (STRETCH). Exercise groups (EXE = TRAINPRO, TRAIN) performed supervised exercise 3 days per week for 12 weeks, while non-exercise groups (NoEXE = PRO, STRETCH) performed a home-based stretching program. TRAINPRO and PRO received 50 g⋅day^(- 1) of whey protein. The primary outcome was change in lean mass assessed through dual energy x-ray absorptiometry. Secondary outcomes examined changes in sarcopenia, assessed through appendicular skeletal mass (ASM) index (kg/m^(2)), body fat %, strength, physical function, quality of life, MetS score and the MetS components of waist circumference, blood pressure, glucose, high-density lipoprotein-cholesterol, and triglyceride levels.
Results
A total of 37 participants were randomized; 32 participated in the intervention (EXE n = 13; NoEXE n = 19). At baseline, 43.8% of participants were sarcopenic and 40.6% met the criteria for MetS. Post-intervention, EXE significantly improved lean mass (d = 0.9), sarcopenia prevalence (d = 0.8), body fat % (d = 1.1), strength (d = 0.8-3.0), and prostate cancer-specific quality of life (d = 0.9) compared to NoEXE (p < 0.05). No significant differences were observed between groups for physical function or MetS-related variables except waist circumference (d = 0.8).
Conclusions
A 12-week resistance training intervention effectively improved sarcopenia, body fat %, strength and quality of life in hypogonadal prostate cancer patients, but did not change MetS or physical function. PRO did not offer additional benefit in improving body composition.
Trial registration
ClinicalTrials.gov: NCT01909440 . Registered 24 July 2013.
Sources & attribution
Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial.
Dawson JK, Dorff TB, Todd Schroeder E, Lane CJ, Gross ME, Dieli-Conwright CM.
BMC cancer · 2018-04-03
DOI: 10.1186/s12885-018-4306-9 ↗PubMed · 29614993 ↗Europe PMC · Recorded licence: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
MoveVitals editorial interpretation · educational content · no individual clinical review recorded
Sources checked 2026-11-01
Practical guides
Read in context
ACSM review of 137 reviews: resistance training works, and few programme details matter
The American College of Sports Medicine pooled 137 systematic reviews (over 30,000 healthy adults) and concluded that resistance training beats no exercise for strength, muscle size, power, endurance and several function tests. Few programme details changed results consistently: heavier loads (80% or more of one-repetition maximum) and 2 to 3 sets favoured strength, and at least 10 sets a week favoured muscle size, while training to failure, exercise type and periodization did not. It summarises reviews rather than new trials, gives no pooled effect sizes, and drew mostly on untrained adults and overlapping source trials.
Medicine & Science in Sports & Exercise
Nearly every resistance training plan beat no exercise; heavy loads led for strength
In a network meta-analysis of randomised trials in healthy adults (178 studies and 5097 people for strength, 119 studies and 3364 people for muscle size), nearly all resistance training prescriptions beat no exercise. Higher-load, multiset, thrice-weekly training ranked best for strength (standardised mean difference 1.60, 95% credible interval 1.38 to 1.82) and higher-load, multiset, twice-weekly training for muscle size (0.66, 0.47 to 0.85). Most prescriptions could not be statistically separated from each other (the 95% interval contained zero in 91% of the comparisons between them) and risk of bias was moderate to high, so the rankings are tentative.
British Journal of Sports Medicine
Muscle-strengthening linked to lower risk of death, heart disease, cancer and diabetes
Pooling 16 prospective cohort studies of adults, people who did muscle-strengthening activity had a 15% lower risk of all-cause mortality (RR 0.85, 95% CI 0.79 to 0.93) and a 17% lower risk of both cardiovascular disease and diabetes (RR 0.83 for each) than people who did none. The pooled mortality curve was lowest at about 40 min/week (RR 0.83), but whether larger amounts help or hurt is unclear. All of this is observational, from mostly US self-reported data, and the authors rated the certainty of evidence as very low for most outcomes.
British Journal of Sports Medicine
Protein supplements and weight training: small extra gains, smaller in older adults
Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.
British Journal of Sports Medicine

